Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Judith Wolf, William Creech, Matthew Ellis

Premium

Vermillion said this week it has appointed Judith Wolf as chief medical officer.

Wolf currently serves as division chief of surgical oncology and vice chair of the department of oncology services at the Banner MD Anderson Cancer Center in Arizona.


ERBA Diagnostics said this week that it has appointed William Creech as vice president of sales and marketing.

Creech was previously vice president of sales and marketing at Vermillion.


Baylor College of Medicine has named Matthew Ellis as its director of the Lester and Sue Smith Breast Center, effective Sept. 1. He succeeds Kent Osborne, who is leaving his post to focus on his other job as director of Baylor's Dan L. Duncan Cancer Center.

Ellis, currently a professor of medicine at Washington University School of Medicine, is focused on studying the molecular underpinnings of breast cancer. BCM received a grant from the Cancer Prevention Research Institute of Texas to recruit Ellis, who will bring a large resource of patient-derived xenografts with him.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.